Aster Capital Management (Difc) LTD Arcus Biosciences, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $198 Billion
- Q3 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 234 shares of RCUS stock, worth $4,696. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234Holding current value
$4,696% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
211Shares Held
67.4MCall Options Held
3.3MPut Options Held
146K-
Black Rock Inc. New York, NY9.76MShares$196 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.63MShares$133 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.33MShares$87 Million0.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.77MShares$75.7 Million0.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74 Million1.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.45B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...